TuHURA completes Kineta acquisition, adds Phase 2 VISTA mAb TBS-2025

TuHURA Biosciences, Inc./NV

Each Kineta share converted into 0.185298 TuHURA shares; ~2.87M shares issued at closing, plus up to ~1.13M additional shares subject to six-month adjustment.
VISTA-inhibiting antibody renamed TBS-2025; TuHURA plans Phase 2 trial in NPM1 mutated AML in 2H 2025.
Acquisition unlocks fourth tranche of $12.5M PIPE financing announced June 3, 2025.
TuHURA believes TBS-2025 can overcome acquired resistance to cancer immunotherapy; exploring ADC synergies.

item 2.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.